This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/3/2026
Good afternoon and welcome to the Ultragenyx third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call. It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations.
Thank you. We've issued a press release detailing our financial results, which you can find on our website at Ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President, Howard Horn, Chief Financial Officer, Eric Harris, Chief Commercial Officer, and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
Thanks, Josh, and good afternoon, everyone. The third quarter was a significant one for all genetics in many ways. In August and September, the FDA approved GenGlycos for Glycogen Stored Disease Type 1a and FiUvi for Sanfilippo Syndrome Type A. These approvals are the result of years of work by our teams and the original scientists, as well as the families Patients, and investigators who took part in the studies. We also saw the disappointing data from the GTX 102 Phase 3 that surprised us despite compelling Phase 2 data, which now has necessitated significant reductions across the company. These actions will bring our cost structure in line with our revenue. This enables us to be well-positioned to continue commercializing our six products for patients with rare diseases and thoughtfully invest in our development programs all while becoming a profitable company next year. While the clinical study myths on an important program that could have created great value has challenged us, we should recognize all that the company has successfully accomplished in 12 years as a public company. We now have six product approvals for the first ever treatment indications across multiple treatment modalities and are driving revenue growth globally of about 20% per year for multiple years heading to a billion plus in revenue and profitability. So while today we acknowledge the setback, when I started the company with $2 million and the secretary, I would have been surprised and inspired to know that we had become a highly respected and admired team of 1,000 professionals treating thousands of patients with rare and also rare diseases worldwide. There is more work to do, and we will today outline the steps we are taking to move the company to its next stage as a profitable company, driving commercialization and development of first-ever treatments for rare diseases. To begin with, I'll focus on the launch of our two new gene therapy products. Both these products provide meaningful and transformative options for these rare disease patients and their families. For people living with glycogen-storey disease type 1a, managing the disease means taking cornstarch every few hours, day and night, because a missed dose can lead to potentially life-threatening hypoglycemia. GenGlycos is the first FDA-approved treatment option for these patients and has the potential to reduce their dependence on cornstarch easing the constant burden of care that defines their lives. The second approval we received in the Corps was for Sanfilippo Syndrome Type A, which is a fatal neurologic disease that begins in early childhood. At birth, these children appear normal, achieving development milestones just like their peers. This continues for the first months, but then stops and over the next few years as the children progressively lose cognition, language, and motor function until they become unresponsive and bedridden for years before death. Until now, families affected by San Felipe syndrome type A have had no approved therapy. Thiuvi is now available to these families as a single IV infusion done as an outpatient, giving them an option to meaningfully change their children's future. This is the hope that gene therapy was supposed to provide. These approvals come at a time that our clinical study failed to prove efficacy with GTX1024A syndrome. Despite having some cases with transformative changes in phase two, Thank you. Thank you. and we are deeply grateful for the contribution of those who are impacted and are committed to providing support and resources to them during this transition. While this process was ongoing, we evaluated our UX701 gene therapy for Wilson disease and found it did not meet our criteria to advance to Phase III. So, given the need to further reduce expenses, we've also made a decision to terminate the UX701 program for Wilson disease rather than try to pursue improvements. The dose finding data, including data from cohort four, showed clinical activity in some patients, but we did not observe a majority of patients achieve a sufficient biochemical response and eliminate standard of care therapy. UX701 demonstrated a favorable safety profile across all cohorts dosed. I do believe there are patients who had meaningful benefits, including some coming off their chelobazine therapy after receiving UX701. I also believe that gene therapy is a rational approach to treating Wilson's disease better than it is treated today. Unfortunately, we are not able to continue investing to optimize the product for Wilson's disease. We are working with clinical sites and patient advocacy groups to support study participants and the broader Wilson community through this transition. And we expect to present the data from the completed study at an upcoming medical or scientific congress to ensure our learnings are available to the broader community. We thank all the patients and investigators for their contributions to the program. These were not easy decisions, but they positioned us to focus on launching Genglycos NFAUV well, continuing to grow our base of commercial products, and achieving profitability in 2027 and going forward. Becoming a self-sustaining company will support our mission to lead the future of rare disease medicine. I'll now turn the call over to Chief Financial Officer Howard Horn, who will provide the detail on our expense reductions and our profitability.
You're reading a preview of the RARE Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing